Hyperpigmentation Disorders Treatment Market Research Report – Forecast till 2027

Hyperpigmentation Disorders Treatment Market: Information by Treatment Type (Topical Drugs, Chemical Peels, and Laser Therapy), Disease Indication (Melasma, Solar and Lentigines), End-User (Hospitals and Others) - Forecast till 2027

ID: MRFR/HC/5993-HCR | February 2021 | Region: Global | 85 Pages         

Hyperpigmentation Disorders Treatment Market

Hyperpigmentation disorders treatment market is accounted for USD 4422.5 million in 2019 and expected to register a 7.60% CAGR during the forecast period

Segmentation

By Treatment Type Topical Drugs Chemical Peels And Laser Therapy
Disease Indication Melasma Solar And Lentigines
End-User Hospitals And Others

Key Players

  • Allergan
  • Inc.
  • Bayer AG
  • EpiPharm AG
  • Episciences
  • Galderma laboratories (Nestle Skin Health S.A)
  • Obagi Cosmeceuticals LLC
  • Pierre Fabre
  • RXi Pharmaceuticals Corporation
  • SkinCeuticals International
  • Vivier Pharma

Drivers

  • rising R&D
Speak to Analyst Request a Free Sample

Hyperpigmentation Disorders Treatment Market Scenario


The hyperpigmentation disorders treatment market is accounted for USD 4422.5 million in 2019 and expected to register a 7.60% CAGR during the forecast period (2019–2027).


Hyperpigmentation disorder refers to harmless skin condition that causes darkened skin patches light brown to black in color. It is a common disorder of the skin and melasma is a common cause of facial hyperpigmentation. There are various types of hyperpigmentation, however, few of the most common such as melasma, solar lentigines, and post-inflammatory hyperpigmentation.


The increasing demands for outpatient and minimally invasive


dermabrasion procedures, include augmented adoption of lasers in pigmentation disorders treatment and growing expenditure on the cosmetics across the world are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by the top players such as new product launches are contributing to the growth of the market. According to the American Society of Plastic Surgeons, the number of dermabrasion cosmetic procedures have increased from 42,218 in 2000 to 88,182 in 2016 with a 109% increase during the estimated period.


The lack of adequate reimbursement policy and high costs involved in the establishment of these centers may hamper the growth of the market during the assessment period.


Key Players


Some of the key players in the hyperpigmentation disorders treatment market Allergan, Inc., Bayer AG, EpiPharm AG, Episciences, Inc., Galderma laboratories (Nestle Skin Health S.A), Obagi Cosmeceuticals LLC, Pierre Fabre, RXi Pharmaceuticals Corporation, SkinCeuticals International, and Vivier Pharma.


Intended Audience



  • Medical devices manufacturers

  • Pharmaceutical Companies

  • Medical devices product distributors and suppliers

  • Healthcare providers

  • Research institutes and academic centers

  • Government associations

  • Market research and consulting


Market Segmentation


The hyperpigmentation disorders treatment market has been segmented on the basis of treatment type, disease indication, end-user, and region.


On the basis of treatment type, the market has been classified as topical drugs, chemical peels, microdermabrasion, laser therapy, phototherapy, and others. the market, by disease indication, has been segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. based on end-user, the market has been segmented into hospitals, aesthetic clinics & dermatology centers, and others. The topical drugs segment is expected to hold the largest market share of the hyperpigmentation disorders treatment market, by treatment type, during the forecast period. Also, by disease indication melasma segment register the considerable growth in comparison to other disease indication.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The hyperpigmentation disorders treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European hyperpigmentation disorders treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The hyperpigmentation disorders treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hyperpigmentation disorders treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


The Americas market is expected to be the second-largest hyperpigmentation disorders treatment market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, favorable reimbursement policies in American countries are contributing to the growth of the market in this region.


Europe is expected to be the third largest hyperpigmentation disorders treatment market during the forecast period owing to the rising in aging population. Moreover, the government of these countries are more focus to provide best treatment option to their citizen. According to the report published by world health organization, Europe aging population will increase from 14 million in 2016 to 19 million in 2020 and 40 million to 2050.


The market in the Middle East & Africa is expected to account for the smallest share of the global hyperpigmentation disorders treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.


The Asia-Pacific are likely to dominate the global hyperpigmentation disorders treatment market owing to the rising awareness of hyperpigmentation disorders, presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, Asia-Pacific is also expected to be the fastest-growing Hyperpigmentation Disorders Treatment market during the forecast period. According to the world bank group, in 2014, China spent 4.96% of gross domestic product (GDP) in healthcare expenditure, whereas in 2015, healthcare expenditure holds 5.32% of GDP. Also, in 2014, India spent 3.63% of GDP on healthcare, however, in 2015 healthcare expenditure holds 3.89% of GDP.


Global Hyperpigmentation Disorders Treatment Market Share, by Region, 2019 (%)


Hyperpigmentation Disorders Treatment Market


Source: MRFR Analysis Segmentation


Hyperpigmentation Disorders Treatment Market, by Treatment Type



  • Topical Drugs

  • Chemical Peels

  • Microdermabrasion

  • Laser Therapy

  • Phototherapy

  • Others


Hyperpigmentation Disorders Treatment Market, by Disease Indication



  • Melasma

  • Solar Lentigines

  • Post-inflammatory Hyperpigmentation

  • Synchrocyclotrons

  • Others


Hyperpigmentation Disorders Treatment Market, by End-User



  • Hospitals

  • Aesthetic Clinics & Dermatology Centers

  • Others


Hyperpigmentation Disorders Treatment Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • South America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • The Middle East & Africa

    • Middle East

    • Africa





Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2019: USD 4422.5 Million
  • 2027: Significant Value
  •   CAGR   7.60% (2019–2027)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Treatment Type, Disease Indication and End-User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Allergan, Inc., Bayer AG, EpiPharm AG, Episciences, Inc., Galderma laboratories (Nestle Skin Health S.A), Obagi Cosmeceuticals LLC, Pierre Fabre, RXi Pharmaceuticals Corporation, SkinCeuticals International, and Vivier Pharma.
      Key Market Opportunities   The Increasing Demands for Outpatient and Minimally Invasive
      Key Market Drivers

  • Increasing Investment in R&D by Major Players
  • consistent stream of new product launches


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Hyperpigmentation disorders are harmless skin conditions that cause a darkening of the skin.

    The hyperpigmentation disorder treatment market was valued at USD 3.9 billion in 2017.

    The hyperpigmentation disorder treatment market is expected to exhibit a strong 7.1% CAGR over the forecast period from 2018 to 2023.

    The leading driver for the market is the increasing investment in R&D by major players and the consistent stream of new product launches.

    Asia Pacific is expected to be the largest and fastest growing regional market for hyperpigmentation disorder treatments over the forecast period.